Gorrissen Federspiel has assisted Sofinnova Partners as lead investor in connection with Hemab Therapeutics’ USD 157M Series C financing round.
Hemab is a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. The financing will support Hemab Therapeutics’ further advancement across multiple clinical programs.
We congratulate Sofinnova Partners, Hemab Therapeutics and the other investors on the investment.
The core team from Gorrissen Federspiel consisted of Niels Bang, Caroline Helene Krestine Boysen, Andreas Nystrup Hoxer Gregersen and Yakub Yildiz.